Baird Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $97
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $63 to $97.
Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $63 to $97.